5 completed, 2 active not recruiting, 2 not yet recruiting, 1 withdrawn. 7 Phase 3, 2 Not applicable, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 4, Active not recruiting 2, Not yet recruiting 1 |
| Not applicable | 2 | Completed 1, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow Leyk: new trials by email Literature Review of Leyk trials Research Report on Leyk
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC Pralsetinib, Leucogen - Non-small Cell Lung Cancer, RET Fusion | Not applicable | Not yet recruiting | Fudan University | 25 | 2026-02-05 | 2026-02-18 |
| A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC 5-fu, Lobaplatin, Placebo - Nasopharyngeal Carcinoma, Leucogen | Phase 3 | Not yet recruiting | Sun Yat-sen University | 132 | 2023-04-01 | 2023-03-22 |
| Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase, Cyclophosphamide, Doxorubicin Hydrochloride - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 2 | Withdrawn | University of Washington | 2018-07-01 | 2018-11-14 | |
| Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine - Acute Myeloid Leukemia, Down Syndrome | Phase 3 | Active not recruiting | Children's Oncology Group | 280 | 2015-12-23 | 2026-08-19 |
| Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 669 | 2014-12-17 | 2026-10-21 |
| Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Asparaginase, Bortezomib, Cytarabine - Acute Myeloid Leukemia, Leukemia Cutis | Phase 3 | Completed | National Cancer Institute (NCI) | 1645 | 2011-07-06 | 2026-06-02 |
| Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Asparaginase, Cyclophosphamide, Cytarabine - Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 63 | 2008-07-14 | 2020-04-13 |
| Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia Asparaginase, Laboratory Biomarker Analysis, Pharmacological Study - Adult Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia | Not applicable | Completed | Children's Oncology Group | 59 | 2008-02-11 | 2019-07-09 |
| Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Asparaginase, Biospecimen Collection, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia | Phase 3 | Completed | Children's Oncology Group | 218 | 2008-01-15 | 2024-07-15 |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Asparaginase, Cyclophosphamide, Cytarabine - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1895 | 2007-01-30 | 2026-06-23 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Burkitt Lymphoma (2) · Leukemia, Myeloid, Acute (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Down Syndrome (1) · Leukemia, Biphenotypic, Acute (1) · Lymphoma (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1) · Nasopharyngeal Carcinoma (1) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1) · Sarcoma, Myeloid (1)
National Cancer Institute (NCI) (4) · Children's Oncology Group (3) · Fudan University (1) · Sun Yat-sen University (1) · University of Washington (1)
United States (8) · Australia (6) · Canada (6) · New Zealand (6) · Puerto Rico (4) · China (1) · Saudi Arabia (1) · Switzerland (1)
Jason N Berman (1) · Joanne M Hilden (1) · Patrick A Brown (1) · Richard Aplenc (1) · Ryan Cassaday (1) · Stuart S Winter (1) · Wanda Salzer (1) · William B Slayton (1)
PMID 28419486, PMID 29812996, PMID 30138085, PMID 30773463, PMID 30987448, PMID 32029509, PMID 32414848, PMID 32552472, PMID 32813610, PMID 33242441, PMID 33651090, PMID 34302711, PMID 34596937, PMID 34855461, PMID 35349331, PMID 36603187, PMID 36815378, PMID 37257143, PMID 37267439, PMID 37556734, PMID 38295280, PMID 40294366, PMID 40533067, PMID 40568722, PMID 41124669, PMID 41592282, PMID 42085603, PMID 42085640
U10CA098543 (6), U10CA180886 (5), P30CA015704 (1)